- £1.40bn
- £1.51bn
- £1.81bn
- 44
- 70
- 98
- 85
2019 December 31st | 2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | Interim Report | ARS |
Standards: | IFRS | IFRS | IFRS | — | IFRS |
Status: | Final | Final | Final | Final | Final |
Total Premiums Earned | |||||
Net Investment Income | |||||
Realized & Unrealized Gains / Losses | |||||
Other Revenue | |||||
Total Revenue | 3,812 | 3,195 | 2,798 | 853 | 1,808 |
Losses, Benefits, and Adjustments | |||||
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3,257 | 4,250 | 2,423 | 1,344 | 1,622 |
Operating Profit | 555 | -1,054 | 375 | -491 | 186 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 369 | 237 | -21.4 | -494 | 172 |
Provision for Income Taxes | |||||
Net Income After Taxes | 302 | 193 | -15.8 | -362 | 129 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 303 | 194 | -15 | -361 | 129 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 286 | 166 | -82.4 | -361 | 129 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.317 | 0.2 | -0.05 | -0.35 | 0.125 |
Dividends per Share |